Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Clinical Trials
624
Trial Phases
5 Phases
Drug Approvals
16
Clinical Trials
Distribution across different clinical trial phases (594 trials with phase data)• Click on a phase to view related trials
Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT07218744
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison, Madison, Wisconsin, United States
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT07213973
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Conditions
- Ovarian Cancer
- Interventions
- Drug: Investigator's choice of chemotherapy
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 466
- Registration Number
- NCT07214779
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Conditions
- Solid TumorsHematologic Malignancies
- Interventions
- Drug: INCA036873
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 280
- Registration Number
- NCT07195916
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Drug: Best available Treatment (BAT)
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT07124078
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next
News
JAK Inhibitor Pipeline Shows Robust Growth with 55+ Therapies in Development Across Multiple Therapeutic Areas
DelveInsight's comprehensive analysis reveals over 50 companies actively developing more than 55 JAK inhibitor therapies, demonstrating significant industry investment in this therapeutic class.
Vitiligo Treatment Pipeline Shows Promise with JAK Inhibitors and Novel Immunotherapies in Phase 3 Trials
Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials.
Incyte Reports Strong Q2 2025 Results with Jakafi Growth and New Drug Approvals
Incyte reported strong second quarter 2025 financial results with Jakafi net revenues of $764 million, representing 8% year-over-year growth driven by increased demand across all indications.
Follicular Lymphoma Market Poised for 6% CAGR Growth Through 2034 as Novel Therapies Advance
The follicular lymphoma market is projected to grow at a 6% CAGR during 2025-2034, driven by increased disease awareness and rising number of clinical trials focused on this slow-growing B-cell malignancy.
MacroGenics Secures $70 Million in ZYNYZ Royalty Deal, Extends Cash Runway Through 2027
MacroGenics received a $70 million upfront payment from Sagard Healthcare Partners through a royalty purchase agreement for ZYNYZ, a PD-1 inhibitor approved for anal canal carcinoma and Merkel cell carcinoma.
ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches
The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy.
Essential Thrombocythemia Market Set for Significant Growth as Novel Therapies Enter Pipeline
Essential thrombocythemia affects approximately 167,000 individuals in the US as of 2024, with 75% of cases linked to JAK2 gene mutations and only one approved therapy currently available in Europe.
Researchers Unveil New Strategies to Harness Tumor Microenvironment for Enhanced Cancer Immunotherapy
Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.
Global GVHD Clinical Trials Review Reveals Key Trends and Strategic Opportunities for 2025
A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.
Promising Pipeline for Mantle Cell Lymphoma Treatment: 22+ Therapies Under Development by 20+ Companies
DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer.